Greater New England Chapter
Participating in a clinical trial is a great way to contribute to curing, preventing, and treating type 1 diabetes (T1D) and its complications. Learn more below about the clinical trials currently recruiting in your area as well as JDRF's easy tool to match you with a clinical trial in 60 seconds.
Choosing to participate in a T1D clinical trial is a very personal decision, but one that can have a significant impact on curing, preventing and treating T1D. There are many opportunities in the Greater New England area to participate in a T1D clinical trial close to home. See below for active opportunities.
Additionally, JDRF has an easy-to-use tool called the Clinical Trials Connection where you can match with a clinical trial in 60 seconds. It asks users some simple questions about themselves before matching them with trials for which they are eligible. Clinical Trials Connection uses your city, distance you’re willing to travel and other characteristics to narrow down hundreds of trials to the ones in which you might be interested. Start your search by visiting jdrf.org/impact/research/clinical-trials today!
If you have any questions, please contact our Greater New England Chapter Clinical Trials Education Volunteer, Amanda Gilchrist.
Updated: February 2, 2024
VIRTUAL
The UP-CBT (Telemedicine-Delivered Unified Protocol for Cognitive Behavioral Therapy for Anxiety and Depression is recruiting participants aged 18-35 living with T1D for > 6 months, A1C 7.5-14%, with anxiety or depressive mood disorder. This project will evaluate a telemedicine-delivered, Unified Protocol for Cognitive-Behavioral Therapy (UP-CBT) enhanced with continuous glucose monitor (CGM) review to target anxiety and depressive symptoms and glycemic control in young adults with type 1 diabetes.
The Immune Function and Progression to T1D study is recruiting participants with T1D of any age and family members of people with T1D of any age. The purpose of the study is to learn more about the genetics and immune function of T1D by comparing people with the disease to family members and normal controls with no family history.
The Symmetry Study is recruiting participants aged 18-29 living with T1D that have seen an endocrinologist in the last 12 months. The purpose of the study is to help understand how relationships with doctors impact the lives of young adults living with type 1 diabetes. If you choose to participate, you will be asked to complete 4 surveys.
The University of Oregon is conducting an online study that aims to better understand the experience of people living with T1D in relation to support and resources. The study is looking for individuals who have been diagnosed for at least 3 months and wear a CGM.
Skylight Health Research is enrolling patients aged 4-30 with T1D not currently using a CGM in a post-market study evaluating Abbott’s continuous glucose monitor, the Freestyle Libre 2. Eligible participants will be provided with the Libre at no cost to them for 6 months and will be compensated for their time and efforts participating in the study.
Trial Net screening is offered at no cost to eligible individuals to evaluate their personal risk of developing T1D. This unique screening can identify the early stages of T1D years before any symptoms appear. It also helps researchers learn more about how T1D develops and plan new studies exploring ways to prevent it. Eligible participants are between the ages of 2.5 and 45 years and have a parent, brother/sister, or child with T1D, between the ages of 2.5 and 20 years and have an aunt/uncle, cousin, grandparent, niece/nephew, or half-brother/sister with T1D, and have NOT been diagnosed with T1D.
The Diabetes Body Acceptance Project is conducting a research study comparing two programs designed to improve body acceptance, reduce body image concerns, and reduce disordered eating behaviors. Female identifying individuals between the ages of 15-30 with T1D who have body image concerns and/or struggle with disordered eating behaviors are invited to participate. Depending on the program you are randomized to you will attend weekly one-hour groups for 6 weeks (virtual or in-person) or watch one hour of videos each week.
University of California, San Francisco is running a virtual study Extended Bolus for Meals in a Closed-Loop System for participants ages 13-18 who use Control IQ to look at the impact of bolus timing on fat/protein.
The REDCHiP clinical trial (Home Video-based Telemedicine to Reduce Hypoglycemia Fear in Parents of Young Children) is recruiting caregivers of children aged 2-6 living with T1D for at least six months. The purpose of this trial is to examine the efficacy of a real-time video-based telemedicine intervention addressing parental fear of hypoglycemia in families of young children with type 1 diabetes.
The T1D Exchange Registry is a research study, conducted over time, for individuals with type 1 diabetes and their supporters. Participants volunteer to provide their data for research (for example, by answering questions in annual surveys). Once enrolled, Registry participants can sign up for other studies on various topics related to type 1 diabetes.
Researchers at the University of Vermont are looking for participants for Activate (The Technology-delivered Physical Activity Program for Adolescents with Type 1 Diabetes). Activate is a 12-week, technology-delivered diabetes behavior-change skills training and physical activity promotion program for adolescents aged 13-17 living with T1D.
NEWLY DIAGNOSED
The DESIGNATE study is recruiting participants aged 18-45 diagnosed with T1D within 18 months. The goal of this study is to see how the experimental study drug, siplizumab, can block or weaken the cells that attack beta cells in the pancreas. This would allow the beta cells to continue to function and produce insulin.
The PETITE-T1D Study is recruiting participants under age 8 with stage 2 diabetes (two T1D-related autoantibodies and dysglycemia). The purpose of this study is to assess the safety and pharmacokinetics of teplizumab in pediatric participants.
The Gladiator Study (A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function) is recruiting participants aged 14-45 with new-onset T1D (within 180 days of diagnosis). This clinical trial will assess whether Ladarixin treatment is effective in preserving beta-cell function and delaying the progression of T1D in adolescent and adult patients.
The JAKPOT-T1D Study is recruiting participants aged 12-35 within 100 days of their T1D diagnosis with an A1C <10%. TrialNet researchers are testing two different treatments – abrocitinib and ritlecitinib – to see if either or both can preserve insulin production in people newly diagnosed with type 1 diabetes. Researchers believe these JAK inhibitors may be able to calm the immune system’s attack on cells that make insulin, while also reducing stress to these cells.
The T1D Relay study is recruiting participants ages 8-45 within 100 days of diagnosis. TrialNet is testing rituximab-pvvr and abatacept, one after the other, to learn if using both treatments extend insulin production in people (ages 8-45) who were newly diagnosed with type 1 diabetes (T1D). Each therapy has a history of safety and effectiveness. Rituximab-pvvr is FDA-approved to treat several autoimmune diseases, including Rheumatoid Arthritis (RA). Abatacept is FDA-approved to treat adult Rheumatoid Arthritis, as well as Juvenile Idiopathic Arthritis (JIA) in children as young as six.
The STOP-T1D Study is recruiting participants ages 12-35 with stage 2 diabetes (have a 50% risk of developing T1D within 2 years, as defined by having two or more diabetes-related autoantibodies and abnormal blood sugar levels) plus at least one high-risk marker. TrialNet researchers are testing a low dose of the immunotherapy drug anti-thymocyte globulin (ATG) to see if it can delay or prevent type 1 diabetes.
MASSACHUSETTS
The PROMISE Study (PRenatal and Obstetric Maternal Exposures and ISlet Autoantibodies in Early Life) is recruiting pregnant women, biological fathers, and their offspring where the offspring has a first degree relative (mother, biological father, full sibling) with T1D. The purpose of this study is to find out more about how exposures during pregnancy, such as having an infection, diet and growth may impact later risk of T1D and islet autoimmunity in the child.
The INHALE-3 Inhaled Insulin Study is recruiting participants over 18 with T1D and an A1C <11%. This study will compare your current insulin delivery method with an FD approved inhaled insulin.
The Multi-Site Eating Disorder Prevention Program for Type 1 Diabetes is looking for participants aged 14-35 living with T1D for at least 1 year and experiencing at least some level of body image concerns. This study aims to test the effectiveness of an evidence-based eating-disorder prevention program specifically targeted for individuals with Type 1 Diabetes (T1D).
The Type 1 Diabetes Management Using a Very Low Carbohydrate Versus Standard Diet randomized-controlled feeding study is recruiting participants aged 18-40 living with T1D for at least 1 year with Stable glycemic control (HbA1c 6.5-9%) who use a CGM and an insulin pump. Participants will be randomized to receive a very low carbohydrate vs. standard carbohydrate diet. Participants will be in the study for 12 weeks and receive all their meals by meal delivery.
A Pilot Study of Fenofibrate to Prevent Kidney Function Loss in Type 1 Diabetes (PERL-FENO) is recruiting participants aged 18-70 living with T1D for at least 8 years with early-to-moderate diabetic kidney disease (DKD) at high risk of ESKD (end-stage kidney disease). The clinical trial is designed to evaluate the effects on the kidney of a generic drug used to lower fats in blood (fenofibrate) that may protect the kidney from damage due to diabetes.
The PRECISION II Study is recruiting participants aged 18-75 living with T1D for at least three months. The purpose of this study is to evaluate the accuracy of the Cambridge Medical Technologies, LLC second generation (2nd Gen) LabPatch glucose sensing system compared to a laboratory glucose analyzer (YSI 2300 STAT Plus) and 2 commercial glucometers, OneTouch Verio and Freestyle Lite.
The Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes is recruiting participants aged 18-65 living with T1D for at least 5 years and have at least two episodes of documented severe hypoglycemia in the 12 months prior to enrollment. This study will evaluate the safety, tolerability, and efficacy of VX-880 infusion in participants with T1D and impaired awareness of hypoglycemia (IAH) and severe hypoglycemia.
The INHALE-1 (Afrezza® INHALE-1 Study in Pediatrics) study is recruiting participants aged 4-17 living with T1D. Afrezza (insulin human) Inhalation Powder is the only inhaled ultra rapid-acting mealtime insulin and is currently FDA-approved for adults. The study will assess the efficacy and safety of Afrezza vs. multiple daily injections of insulin, both in combination with basal insulin.
The Joslin Heart and Kidney Study is recruiting participants ages 25-65 diagnosed with T1D before 41 with normal or moderately decreased kidney function. The goal of this study is to further understand the connection between changes in the cardiovascular system and early kidney disease in people with type 1 diabetes. This information may lead to future prevention and treatment options.
The TANGO Study is recruiting participants with T1D ages 65 and older on MDI or use an insulin pump (Medtronic or Insulet). This study assesses a new technology that aids the communication of health information amongst patients, family members/caregivers, and providers. The study is also looking to determine if this technology is a helpful tool in diabetes management.
The Bone Health in Youth With Type 1 Diabetes study is looking for participants aged 6-20 living with T1D (as well as non-diabetic peers) to participate in an observational study to determine Bone Mineral Accrual and Microarchitecture in children and young adults with T1D. The investigators will examine blood and urine hormone levels as well as measures of bone density. They will also be collecting data regarding physical activity via use of wearable accelerometers.
The Understanding and Optimizing Care for Young Adults With Type 1 and Type 2 Diabetes Mellitus Transitioning to Adult Care study is looking for participants aged 18-30 living with T1D. Researchers will compare an innovative care model for young adults with diabetes and those in the usual care model for adult diabetes management at Massachusetts General Hospital (MGH) Diabetes Center. Participants in the research study will be asked to complete a series of three survey questionnaires over the timeframe of the study.
The Omnipod 5 System Compared to Pump Therapy study is recruiting participants aged 18-70 living with T1D for at least 1 year who are not currently using automated insulin delivery (AID) devices. Participants will undergo a 14-day outpatient, standard therapy phase during which sensor and insulin data will be collected. This will be followed by a 90-day outpatient phase where subjects will either use the Omnipod 5 system or continue to use their personal insulin pump with the study provided continuous glucose monitoring system.
The Healthy And Positive Pathways for Young People With Type 1 Diabetes (HAPPY T1D) clinical trial is recruiting participants aged 14-25 with type 1 diabetes for at least 1 year and suboptimal diabetes control (A1c 7-13%). This 2-year randomized clinical trial will implement and assess the impact of a behavioral/psychoeducational intervention to reduce diabetes distress and improve glycemic outcomes to optimize short-term and long-term health.
The Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes is recruiting participants aged 12-17 living with T1D for at least two years. The study is investigating if repeat bacillus Calmette-Guérin (BCG) vaccinations can confer a beneficial immune and metabolic effect on pediatric Type 1 diabetes. Eligible volunteers will either be vaccinated with BCG twice, one month apart or receive a placebo treatment.
The CIAO Study is recruiting participants ages 16-35 or 65+ on MDI. The study uses an electronic dose-recording device with new insulin pen cap technology.
NEW HAMPSHIRE
The Sweetgoals for Type 1 Diabetes study is looking for participants aged 19-29 living with T1D to test an app and web-delivered intervention designed to improve glycemic control. All participants will receive the “core” digital intervention and the SweetGoals app, focused on self-monitoring and goal setting. Efficacy of two independent intervention components (incentives for adherence and web health coaching) will be tested.
RHODE ISLAND
The Guardian Connect study is looking for participants aged 2-80 living with T1D at least 6 months (subjects 2-6 years old) or at least 12 months (subjects 7-80 years old) on MDI (multiple daily injections) currently using or willing to use an insulin pen. The study will collect sensor, insulin, sleep, activity, and food/meal data.
VERMONT
The Eversense® Non-adjunctive Use Post Approval Study (NA-PAS) is recruiting adults with T1D 18 and over not currently using a CGM (continuous glucose monitor). The study is evaluating the effectiveness of Eversense CGM System non-adjunctively compared to self-monitoring of blood glucose (SMBG) using a blood glucose (BG) meter in participants. The investigation will include both clinic visits and home use of Eversense CGM System.
Resources
What Are Clinical Trials Video
Match To Clinical Trials in 60 Seconds
Meet Your CTEV: Amanda Gilchrist
After learning that many clinical trials are slowed down due to low participation, Amanda’s family became involved in this important step to move research forward. In her new role, Amanda is excited to share the importance of clinical trials in T1D research and to encourage T1D families to learn about the many different clinical trial options available to them, both locally and virtually.
Amanda became involved in JDRF in 2020 when her then 4-year-old daughter was diagnosed. The community, education, and resources for JDRF families was such an incredibly important support following her daughter’s diagnosis. The JDRF T1D community and connections became even more important to her family when Amanda was diagnosed with T1D in 2021. With two T1Ds in the family, they have a lot of clinical trial experience to share!
Amanda has a husband (Bob), a daughter (Emmie), and a son (Callen). They live in North Reading, MA and they enjoy spending time as a family reading, visiting Canobie Lake Park, and playing board games. She is excited to take on this volunteer position and looks forward to connecting with you.
More from the Greater New England Chapter